Gemfibrozil
| Evidence Level: L4 | Predicted Indications: 9 |
Table of Contents
Gemfibrozil: From Hypertriglyceridemia to Rheumatoid Arthritis
One-Sentence Summary
Gemfibrozil is a lipid-lowering drug originally used to treat hypertriglyceridemia. The TxGNN model predicts it may be effective for rheumatoid arthritis, but the support is limited to 4 publications, all preclinical or only indirectly relevant, and no clinical trials. Two other predictions, HIV infectious disease (in practice, lipid disorders in HIV patients) and hypoalphalipoproteinemia, have stronger clinical evidence and are discussed in the conclusion.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypertriglyceridemia |
| Predicted New Indication | Rheumatoid arthritis |
| TxGNN Prediction Score | 0.9990 |
| Evidence Level | L4 |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, gemfibrozil is a fibrate that acts as a PPAR-alpha agonist. Its efficacy in hypertriglyceridemia is established.
PPAR agonism has anti-inflammatory and immunomodulatory effects, including effects on T-cell differentiation and cytokine signalling. This offers a plausible, but indirect, route to benefit in an autoimmune inflammatory disease such as rheumatoid arthritis. Supporting signals include a preclinical study of bezafibrate (a pan-PPAR agonist) in experimental arthritis and a rat study of gemfibrozil combined with a reduced steroid dose.
These are indirect signals only. No human data in rheumatoid arthritis were identified.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 30074417 | 2019 | Preclinical (rat) | Modern Rheumatology | Gemfibrozil with a reduced prednisolone dose gave a management picture similar to the full steroid dose in an adjuvant-induced arthritis model |
| 41207105 | 2026 | Preclinical (animal) | International Immunopharmacology | Bezafibrate, a pan-PPAR agonist, attenuated experimental rheumatoid arthritis through PPAR-dependent anti-inflammatory pathways (not gemfibrozil) |
| 20083653 | 2010 | Preclinical (mechanistic) | Journal of Immunology | Myelin basic protein priming reduced Foxp3 expression in T cells via nitric oxide; background on regulatory T-cell biology |
| 18039017 | 2007 | Review | American Journal of Clinical Dermatology | Review of palmar erythema; low relevance |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02142074 | TEVA-GEMFIBROZIL | Not specified | Not specified |
Safety Considerations
Contraindication-related diseases (from the knowledge graph, not label text): liver disease, gallbladder disease, cholelithiasis, cholecystolithiasis, choledocholithiasis, primary biliary cholangitis, impaired renal function, thrombocytopenia, anaemia (including macrocytic anaemia), leukopenia and Reynolds syndrome.
Drug interactions: The interaction screen returned 100 records. The main ones among the 20 listed are:
- Major: rosuvastatin and simvastatin (increased risk of muscle toxicity, including rhabdomyolysis), pioglitazone, repaglinide, loperamide and eluxadoline
- Moderate: chenodeoxycholic acid, chlorpropamide, tolazamide, nateglinide, rosiglitazone, rifaximin, and multiple insulins (glucose-lowering effects may be potentiated)
Package insert warnings and contraindications for the Canadian product were not available. Please refer to the package insert for the full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: For rheumatoid arthritis, the high TxGNN score is supported only by animal and mechanistic studies, with no clinical trials and no human data. Given the safety signals (hepatobiliary, renal, haematological and major interactions), there is no basis to advance this indication now.
Two other predictions are more advanced and may be better candidates for follow-up as research questions:
- HIV-associated dyslipidaemia (L2): a randomized, double-blind study of gemfibrozil for protease inhibitor-associated hypertriglyceridaemia (PMID 12409741) exists. However, this is essentially a lipid indication within HIV patients, not an antiviral effect, and so is close to the original use.
- Hypoalphalipoproteinemia (L2): several small randomized or crossover studies from 1989 to 2000 showed lipid effects, but with small samples and surrogate endpoints only.
To proceed, the following is needed:
- Detailed mechanism of action data (MOA)
- Package insert warnings and contraindications from Health Canada
- Human data for rheumatoid arthritis (for example, an exploratory clinical study), beyond animal models
- A drug interaction management plan, especially for statins and glucose-lowering agents
- Approved indication text and dosage form for the Canadian product
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.